REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

RGX-314 produced by the NAVXpress platform process has been well-tolerated and demonstrated a similar clinical profile to the initial adherent cell culture process. NAVXpress platform process is incorporated in the two ongoing pivotal trials and is expected to be used for future commercialization of RGX-314; the two pivotal trials are expected to support BLA submission in 2022. Company to host live webcast with wet AMD Key Opinion Leaders to discuss new interim Phase II bridging study data, today, Saturday, February 11, at 11:30 a.m. ET.

ROCKVILLE, Md., Feb. 11, 2023 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced results from a Phase II bridging study evaluating the pharmacodynamics, safety and efficacy of RGX-314, a potential one-time therapy delivered subretinally using cGMP material produced by the company’s NAVXpress bioreactor platform process. The data is being presented at the Angiogenesis, Exudation, and Degeneration 2023 Conference by Charles C. Wykoff, M.D., PhD., Director of Research at Retina Consultants of Texas; Chairman of Research, Retina Consultants of America; and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital.

“The interim results observed in the Phase II bridging study show a similar clinical profile between our manufacturing processes. We believe our approach, focused on early product quality and process control, allows us to efficiently transition from clinical trials to commercial readiness,” said Curran Simpson, Chief Operating Officer of REGENXBIO. “This update provides validation of our plans for the NAVXpress platform process to support the production of RGX-314 in anticipation of future commercialization.”

“There is a significant need for treatment options that can reduce the burden of frequent injections for wet AMD patients while maintaining optimal function and anatomic outcomes,” said Dr. Wykoff. “The clinical profile of RGX-314 manufactured using the commercial-scale process is encouraging, as is the potential of a one-time therapy for the treatment of wet AMD.”

Interim Data Summary from the Phase II Bridging Study of RGX-314 using Subretinal Delivery
The Phase II bridging study is designed to evaluate RGX-314 using subretinal delivery across two dose levels (6.4×1010 GC/eye and 1.3×1011 GC/eye) in 60 patients with wet AMD. At each dose level, patients are assigned into two cohorts, with half of the patients at each dose level receiving RGX-314 produced by the NAVXpress platform process, and the other half receiving RGX-314 produced by the adherent cell culture manufacturing process that was used in the Phase I/IIa trial of RGX-314 for the treatment of wet AMD. The primary endpoint of the study is RGX-314 target protein concentration in the eye at Month 6. Secondary endpoints include safety and tolerability, change from baseline in Best Corrected Visual Acuity (BCVA), change in central retinal thickness (CRT) and need for supplemental anti-VEGF injections.

As of November 14, 2022, RGX-314 was well tolerated across 46 patients dosed in cohorts at both dose levels. Five SAEs were reported, none of which were considered related to RGX-314. In the high dose cohorts, all common treatment emergent adverse events (TEAEs) through 6 months in the study eye were mild or moderate and included post-operative conjunctival hemorrhage, post-operative inflammation and retinal pigmentary changes.

The two high dose cohorts have fully enrolled and completed six month visit assessments. Data presented at Angiogenesis highlighted the results from these cohorts (n=30). In these cohorts, target protein concentrations in the eye were similar between the manufacturing processes. Patients in the two high dose cohorts also demonstrated stable to improved BCVA and CRT, and meaningful reductions in anti-VEGF burden, with a majority of subjects injection-free.

Pivotal Trials for the Treatment of RGX-314 for wet AMD using Subretinal Delivery
To support future commercialization of RGX-314, the cGMP material produced by the Company’s NAVXpress platform process has been incorporated in the ongoing pivotal trials, ATMOSPHERE® and ASCENT, for the treatment of wet AMD using RGX-314 delivered subretinally. These pivotal trials are multi-center, randomized, active-controlled trials to evaluate the efficacy and safety of a single-administration of RGX-314 using subretinal delivery versus standard of care in patients with wet AMD. The two pivotal trials are designed to evaluate the same dose levels being used in the Phase II bridging study.

“The RGX-314 program is central to our ‘5x’25’ strategy to have five AAV Therapeutics either on the market or in late-stage development by 2025. Our NAVXpress platform process is producing cGMP material at the REGENXBIO Manufacturing Innovation Center and has supported the advancement of several of our on-going clinical programs,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. “We are one of only a few gene therapy companies with a cGMP facility capable of producing at scales of up to 2,000 liters, which we believe represents a key differentiator for REGENXBIO that we expect to use across our ongoing clinical trials to support accelerating the development of our AAV Therapeutics, including RGX-314.”

A live discussion of the Phase II bridging study data with Dr. Wykoff and Dr. Peter Kaiser, Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine and Cole Eye Institute, and Dr. Steve Pakola, Chief Medical Officer of REGENXBIO will stream on the “Investors” events page of the REGENXBIO website at 11:30 a.m. ET. The presentation is available on the “Presentations and Publications” section of the REGENXBIO website at

About RGX-314
RGX-314, being developed in collaboration with AbbVie, is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions. RGX-314 consists of the NAV® AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). RGX-314 is believed to inhibit the VEGF pathway by which new, leaky blood vessels grow and contribute to the accumulation of fluid in the retina.

REGENXBIO is advancing research in two separate routes of administration of RGX-314 to the eye, through a standardized subretinal delivery procedure as well as delivery to the suprachoroidal space. REGENXBIO has licensed certain exclusive rights to the SCS Microinjector® from Clearside Biomedical, Inc. to deliver gene therapy treatments to the suprachoroidal space of the eye.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9, and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a “5 x ’25” strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.


Dana Cormack
Corporate Communications
[email protected] 

Chris Brinzey
ICR Westwicke
[email protected]